The anti-CCP work culminated in the therapeutic programs that formed the foundation of clinical stage biopharma company Citryll, whom he served on the board of directors until his unexpected passing. In the early days of developing the discovery of the NETosis antagonist, as one does with any first in class therapeutic biotech, we spent long days with Jos and many plane trips (with occasionally too many margueritas) discussing how to progress our surprise discovery into a clinical drug development program. Was it real was a central question to us, and yes it was real! The many discussions with European and American researchers, clinicians, pharma colleagues and interested investors brought us where Citryll is now, and we are deeply saddened his involvement with Citryll has come to a sudden stop.